Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype

Dang, Harry; Jiang, Allan; Kamel‐Reid, Suzanne; Brandwein, Joseph; Chang, Hong

doi:10.1016/j.humpath.2012.04.008

Cited by 13 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prognostic role of CD15 expression has been tested in a number of previous studies with conflicting results (Table ). A possible explanation relies in the different type of population reported by Dang et al, who selected elderly AML patients with a normal karyotype; in this subgroup of patients, they were unable to document the favorable prognostic role of CD15 reported by Campos et al and Tien et al and further confirmed in our study on a larger series of AML patients of all ages. It is worth noting that in our study, CD15 positivity resulted as the most powerful independent predictor of CR achievement (Table ).…”

Section: Discussioncontrasting

confidence: 68%

“…Different surface antigens have been retrospectively evaluated to test a possible prognostic value, but the results have not been consistent, owing also to the relatively small number of patients analyzed and to the differences in the selection of patient cohorts, types of treatment, thresholds of antigen positivity, and immunophenotyping methodologies. In Table , these conflicting results are reported for the CD13, CD15, CD11b, CD34, CD117, and CD14 antigens.…”

Section: Discussionmentioning

confidence: 99%

“…It is also expressed in patients with Hodgkin disease, some B‐cell chronic lymphocytic leukemias, and acute lymphoblastic leukemias and on blasts of patients with AML . Its prognostic role has been tested in different studies, including or not acute promyelocytic leukemia (APL), with conflicting results, and its significance is still unclear …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia

Chisini

Stefanizzi

Ceglie

et al. 2016

Hematological Oncology

View full text Add to dashboard Cite

The prognostic role of CD15 in acute myeloid leukemia (AML) has been tested in different studies with conflicting results. To address this issue, we retrospectively evaluated a cohort of 460 AML patients of all ages with the exclusion of acute promyelocytic leukemia (M/F 243/217, median age 50.6 years [range 0.9-81.2]) intensively treated at our institute between January 1999 and December 2010. CD15 positivity was found in 171 of 406 evaluable patients (42.1%). Complete remission (CR) was achieved by 334 patients (72.6%), while 82 (17.8%) were resistant and 44 (9.6%) died during induction: the median CR duration was 15.5 months (range 0.6-176.0), with 2-year disease-free survival rate of 45.1% (95% confidence interval 39.6-50.6). The median overall survival was 14.4 months (range 0.3-177.0), with 2-year overall survival rate of 42.2% (95% confidence interval 37.5-46.9). At univariate analysis for CR achievement, age < 60 years (P < .001), World Health Organization classification (P = .045), low-risk karyotype (P < .001), no high-risk karyotype (P = .006), positivity for AML-ETO (P = .004)/CBFβ-MYH11 (P = .003)/CD15 (P = .006)/CD11b (P = .013), negativity for FLT3-ITD (P = .001), Hb > 8 g/dL (P = .020), and white blood cell < 50 × 10 /L (P = .034) had a favorable impact. At a multivariate logistic regression model, CD15 positivity (P = .002), age < 60 years (P = .008), white blood cell < 50 × 10 /L (P = .017), and low-risk/no high-risk karyotype (P = .026/P = .025) retained an independent prognostic role on CR achievement. The baseline assessment of CD15 positivity appears to have a role in the risk evaluation for CR achievement in AML patients undergoing intensive chemotherapy and should be assessed in prospective studies together with other clinical and biologic features already reported.

show abstract

Section: Discussioncontrasting

confidence: 68%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia

Chisini

Stefanizzi

Ceglie

et al. 2016

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Currently, studies on the immunology and cytogenetic features of FLT3-ITD mutation-positive AML are scarce (22,23). Among the 14 cases of AML with t(11; 12) (p15; q13) reported, including the present case, 21% (3 cases) demonstrated an FLT3-ITD mutation.…”

Section: Discussionmentioning

confidence: 65%

Acute monocytic leukaemia with t(11; 12) (p15; q13) chromosomal changes: A case report and literature review

Hong

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Acute myeloid leukaemia (AML) is a type of heterogeneous disease derived from haematopoietic stem cells. Cytogenetic characterisation is essential for diagnosis and prognosis stratification. Here, we present the case of a 43-year-old female diagnosed with leukaemia, who demonstrated a rare chromosomal change of t(11; 12) (p15; q13) along with a positive FLT3-ITD mutation. The patient had a white blood cell count of 76.41x10 9 /l. Bone marrow morphology revealed that monoblasts accounted for 25.5% of cells, and premonocytes accounted for 49.0%. This patient strongly responded to idarubicin and Ara-c (cytarabine) chemotherapy, which rapidly eliminated the leukaemia cell clones. However, the proliferation rate of the leukaemia cells was high during the intermission of chemotherapy. Subsequently, following two courses of chemotherapy, full haematological remission could not be attained. AML patients with t(11; 12) (p15; q13) combined with FLT3-ITD mutations are expected to have a short life expectancy; however, early haematopoietic stem cell transplantation therapy may improve the treatment outcome for these patients.

show abstract

“…Con una respuesta completa a la terapia de inducción en pacientes de bajo riesgo de 90.9 %, de riesgo intermedio 77.8 % y riesgo alto de 60 % 5 . Harry Dang 12 , et al, en su estudio "Prognostic value of inmunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype" en su estudio demostró que la expresión de CD56 fue un factor independiente de mal pronóstico, con menor porcentaje de remisión completa (p = 0.021) y sobrevida libre de evento (p=0.003), además la expresión de CD34 se correlaciono con menor sobrevida global (13 meses vs 22.6 meses, p = 0.015) 12 .…”

Section: Tablaunclassified

Factores Asociados Al Pronóstico Y Supervivencia en Pacientes Adultos Hospitalizados Con Diagnóstico De Leucemia Mieloide Aguda Del Hospital Nacional Dos De Mayo Período 2014 a 2016

Cruz-Vargas¹

2019

RFMH

View full text Add to dashboard Cite

Introduccion: La supervivencia en pacientes con diagnóstico de Leucemia Mieloide Aguda (LMA) se puede ver afectada por diversos factores clínicos, citogenéticos e inmunofenotípicos. Objetivo: Determinar las características del tamizaje para cáncer CCU en 08 establecimientos de salud (EESS) de Lima Metropolitana sedes del Internado Médico de la FAMURP en el 2017. Métodos: Se realizó un estudio observacional, transversal, retrospectivo y analítico, basado en la revisión de historias clínicas de todos los pacientes adultos con diagnóstico de Leucemia Mieloide Aguda, diagnosticados en Abril del 2014 a diciembre de 2016 y se realizó un seguimiento para determinar su desenlace final a 2 años asociándolo a la presencia de factores condiciones de mortalidad. La muestra final fue de 39 pacientes. Resultados: De los 39 pacientes 16 (41%) fueron mayores de 60 años, 23 (59%) fueron menores de 60 años, 13 de los pacientes (33%) presentaron una cifra de Leucocitos mayor a 50 000 al diagnóstico y 26 (77%) presentaron una cifra menor a 50 000. 33 pacientes presentaron una Leucemia de Novo (84%) y 6 (16%) presentaron una Leucemia secundaria a un Síndrome Mielo Displásico o algún antecedente de quimioterapia previa. No se obtuvo datos de todos los pacientes según clasificación Franco Americano Británica (FAB), Inmunofenotipo y Cariotipo. La supervivencia se evaluó en 3 tiempos, a los 6 meses, al año y a los 2 años desde la fecha del diagnóstico, teniendo que a los 6 meses la sobrevida global de los 39 pacientes había sido el 69 % (25), al año 49% (18) y a los 2 años se mantuvo en el mismo rango. La supervivencia al año y 2 años del diagnóstico se obtuvo el mismo Odds Ratio (OR) de 4.5 para la variable Leucocitos al diagnóstico mayor a 50 000 (IC 95%: 1.008-20.507), considerándola como un factor de riesgo para mortalidad. En el análisis de supervivencia de la misma variable mencionada con la supervivencia al año y dos años que la supervivencia fue significativamente menor en el grupo de pacientes con leucocitos al diagnóstico mayor a 50 000. Conclusión: En nuestra población de estudio se encontró significancia estadística al momento de evaluar la variable Leucocitos al diagnóstico mayor a 50 000 encontrándola como factor asociado a la mortalidad a 2 años, con una supervivencia significativamente mayor que el grupo de pacientes con Leucocitos al diagnóstico menor a 50 000.

show abstract

Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype

Cited by 13 publications

References 33 publications

Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia

Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia

Acute monocytic leukaemia with t(11; 12) (p15; q13) chromosomal changes: A case report and literature review

Factores Asociados Al Pronóstico Y Supervivencia en Pacientes Adultos Hospitalizados Con Diagnóstico De Leucemia Mieloide Aguda Del Hospital Nacional Dos De Mayo Período 2014 a 2016

Contact Info

Product

Resources

About